Clinical Trial Update: An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder [Phase 3]

View source ↗

Summary

This is a Phase 3 effectiveness and safety study of CONCERTA (methylphenidate hydrochloride) in adolescents with attention-deficit/hyperactivity disorder, which…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)
• METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED